George S. Golumbeski
Independent Chairman of the BoardDr. George S. Golumbeski Ph.D., serves as the Chairman of the Board at Acumen Pharmaceuticals, Inc. since November 2025. Dr. Golumbeski is Non-Executive Director of Faron Pharmaceuticals Oy from May 5, 2026. He is a Director at Judo Bio Inc. and Setara Biosciences, Inc. He serves on Board of Directors at Judo Bio. He is Observer of Mahzi Therapeutics Inc. from 2025. He serves as Chairman of National Audubon Society, Inc. from September 28, 2024. he was elected Treasurer of the Board in 2017 and has served as Vice Chair since 2021. He serves as Director of Ananke Therapeutics Inc. and Tucana Biosciences Inc. He serves as Independent Director of Mural Oncology plc since July 30, 2024. He serves as Director of Vicinitas Therapeutics, Inc. He is Partner of DROIA Ventures. He serves as Chairperson of the Board at Actio Biosciences Inc. He was Member of Scientific Advisory Board of Foresite Labs. He serves as Venture Advisor at Vertex Ventures HC. He served as Executive Advisor since joining on October 29, 2020. He serves as Director at Verseau Therapeutics. George served as Independent Director at Chroma Medicine, Inc. from May, 2022. he had been an Independent Director at Enanta Pharmaceuticals, Inc. since February 11, 2014 until March 2, 2021. He served as Deputy Chairman of Supervisory Board at MorphoSys AG since April 2020 until May 2024. He was Member of Supervisory Board since May 17, 2018 until May 2024. He was Chairman of the Business Advisory Board at 1910 Genetics Inc. he served as a Non-Independent Director of Corbus Pharmaceuticals Holdings, Inc. since July 6, 2020 until September 2020. he served as Chairman of Aura Biosciences, Inc. until March 2021. He was Chairman of the Board at Carrick Therapeutics, Ltd. since October 11. He was President of GRAIL, Inc. and a privately held biotechnology company, from August 2018 to August 2019. he served as Executive Vice President of Business Development at Celgene Corporation from March 2009 to April 2018 and served as its Senior Vice President of Business Development since 2009 where he and his team were responsible for the full array of worldwide business development activities. He joined Celgene in 2009. He served as a Venture Partner at Arch Venture Partners, L.P. He serves as Executive Advisor and Board Member of KSQ Therapeutics. Prior to Celgene, he served as the Chief Executive Officer of Nabriva Therapeutics plc from July 2008 to March 2009. Prior to Nabriva, he served as Vice President of Business Development, Licensing and Strategy for Novartis-Oncology from 2002 to 2008 and was responsible for the overall results of the business unit franchise. He is a biotechnology executive with experiences in the biotechnology industry. He served as Vice President of Research & Development at Elan Biopharmaceuticals, from 2001 to 2002 where he was a Member of the research and development management team primarily responsible for the research and development pipeline and drug candidate selection. He held several business and corporate development positions of increasing responsibility at EMD Pharmaceuticals, Pierce Chemical Company and Promega Corporation. Earlier in his career. He held senior positions at Elan Pharmaceuticals and at Schwarz Pharma, where he led the effort to in-license rotigotine and lacosamide (now both approved agents). He serves as Independent Director of Shattuck Labs, Inc. since January 2018 and serves as its Independent Chairman of the Board since October 2021. He is director of Sage Therapeutics, Inc. he joined Sage Therapeutics, Inc. on January 22, 2019. He was a Director of Tizona Therapeutics, Inc. since September 2016. He served as a Director of Acceleron Pharma Inc. since 2011 until 2018. He served as a Trustee of BioNJ Inc. until February 25, 2016. He served as a Director of Celgene Corporation. He has served as a Trustee of the Keck Graduate Institute since 2013. George received a B.A. in Biology from the University of Virginia and a Ph.D. in Genetics from the University of Wisconsin-Madison.
Positions
- Company NameShattuck Labs, Inc.Stock CodeSTTKPositionIndependent Chairman of the BoardColleagues
- THTaylor H. SchreiberCo-Founder, CEO & Director
- GSGeorge S. GolumbeskiIndependent Chairman of the Board
- ARAndrew R. NeillChief Financial Officer
- ANArunthathy Nirmalini PanditeChief Medical Officer
- BHBrad HuckabeeVice President of Accounting & SEC reporting
- AAAbhinav A. ShuklaChief Technical Officer
- NWNeil W. GibsonIndependent Director
- HMHelen Marie BoudreauIndependent Director
- CBClay B. SiegallIndependent Director
- Company NameAcumen Pharmaceuticals, Inc.Stock CodeABOSPositionIndependent Chairman of the BoardColleagues
- DJDaniel J. O'ConnellCEO & Director
- JDJames DohertyPresident & Chief Development Officer
- MZMatt ZugaCFO & Chief Business Officer
- GAGrant A. KrafftCo-Founder
- CECaleb E. FinchCo-Founder
- JLJeffrey L. C. IvesIndependent Director
- LSLaura StoppelIndependent Director
- KCKimberlee Cobleigh DrapkinIndependent Director
